Thomas M Mcdermott, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 7210 Beacon Woods Dr, Hudson, FL 34667 Phone: 727-863-1521 |
Julia Ann Elliott, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 7210 Beacon Woods Dr, Hudson, FL 34667 Phone: 727-863-1521 |
Dr. Daniel Howard Bender, M.D. Physical Medicine & Rehabilitation - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 8811 State Road 52, Suite 21, Hudson, FL 34667 Phone: 727-861-2277 Fax: 727-861-2062 |
Suzanne Elizabeth Wood, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 13823 Echo Mountain Dr, Hudson, FL 34667 Phone: 319-560-5956 |
Rachel Lopez, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 13910 Fivay Rd Ste 6, Hudson, FL 34667 Phone: 727-869-9479 |
Mr. Christopher A Reyher, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 7544 Jacque Rd, Hudson, FL 34667 Phone: 727-697-2200 Fax: 727-863-8774 |
News Archive
Embryos derived from oocytes (eggs) cryopreserved by the vitrification method are just as likely to produce an on-going pregnancy as those involving fresh oocytes, the 26th annual meeting of the European Society of Human Reproduction and Embryology heard today. Dr. Ana Cobo, Cryobiology Unit director at Institut Universitari - IVI Valencia, Valencia, Spain, told delegates that the results of her team's research would make egg donation both easier and safer in the future.
Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information.
A new device developed by a physician at the University of Arkansas for Medical Sciences and a researcher at the University of Arkansas at Little Rock could soon be available to treat stroke more effectively.
Octapharma USA has launched a comprehensive Web site for wilate® at www.wilateusa.com to provide von Willebrand disease healthcare professionals and patients with easily accessible information, news and updates. The U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate® (von Willebrand Factor/Factor VIII Concentrate, Human), the first replacement therapy developed specifically for von Willebrand Disease (VWD).
› Verified 2 days ago